PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance

被引：0
|
作者：
Dedes, K. J.
Wilkerson, P.
Wetterskog, D.
Lambros, M. B.
Natrajan, R.
Tan, D. S.
Campion-Flora, A.
Rodrigues, D. N.
Gauthier, A.
Daley, F.
Lord, C. J.
Kaye, S. B.
Ashworth, A.
Reis-Filho, J. S.
机构：
[1] Inst Canc Res, London SW3 6JB, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Inst Curie, Paris, France
来源：
MODERN PATHOLOGY | 2012年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1113
引用
收藏
页码：265A / 265A
页数：1
相关论文
共 50 条
  • [1] PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance
    Dedes, K. J.
    Wilkerson, P.
    Wetterskog, D.
    Lambros, M. B.
    Natrajan, R.
    Tan, D. S.
    Campion-Flora, A.
    Rodrigues, D. N.
    Gauthier, A.
    Daley, F.
    Lord, C. J.
    Kaye, S. B.
    Ashworth, A.
    Reis-Filho, J. S.
    [J]. LABORATORY INVESTIGATION, 2012, 92 : 265A - 265A
  • [2] Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
    McMullen, Michelle
    Karakasis, Katherine
    Madariaga, Ainhoa
    Oza, Amit M.
    [J]. CANCERS, 2020, 12 (06) : 1 - 18
  • [3] Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients
    Senturk Kirmizitas, Tugce
    van den Berg, Caroline
    Boers, Ruben
    Helmijr, Jean
    Makrodimitris, Stavros
    Dag, Hamit Harun
    Kerkhofs, Marijn
    Beaufort, Corine
    Kraan, Jaco
    van IJcken, Wilfred F. J.
    Gribnau, Joost
    Garkhail, Pakriti
    Boer, Gatske Nieuwenhuyzen-de
    Roes, Eva-Maria
    van Beekhuizen, Heleen
    Gunel, Tuba
    Wilting, Saskia
    Martens, John
    Jansen, Maurice
    Boere, Ingrid
    [J]. GENES, 2024, 15 (06)
  • [4] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Ying Chen
    Lei Zhang
    Quan Hao
    [J]. Archives of Gynecology and Obstetrics, 2013, 288 : 367 - 374
  • [5] Olaparib, PARP1 inhibitor in ovarian cancer
    Marchetti, Claudia
    Imperiale, Ludovica
    Gasparri, Maria Luisa
    Palaia, Innocenza
    Pignata, Sandro
    Boni, Terenzio
    Bellati, Filippo
    Panici, Pierluigi Benedetti
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
  • [6] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Chen, Ying
    Zhang, Lei
    Hao, Quan
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (02) : 367 - 374
  • [7] Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
    Gross, Maya
    Spencer, Ryan J.
    [J]. CASE REPORTS IN OBSTETRICS AND GYNECOLOGY, 2022, 2022
  • [8] The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib
    Wichmann, Catharina
    Klotz, Daniel Martin
    Zeiler, Hans-Joachim
    Hilger, Ralf Axel
    Gruetzmann, Konrad
    Krueger, Alexander
    Aust, Daniela
    Wimberger, Pauline
    Kuhlmann, Jan Dominik
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 850 - 859
  • [9] Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
    Wilkerson, Paul M.
    Dedes, Konstantin J.
    Samartzis, Eleftherios Pierre
    Dedes, Ioannis
    Lambros, Maryou B.
    Natrajan, Rachael
    Gauthier, Arnaud
    Piscuoglio, Salvatore
    Topfer, Chantal
    Vukovic, Vesna
    Daley, Frances
    Weigelt, Britta
    Reis-Filho, Jorge S.
    [J]. ONCOTARGET, 2017, 8 (04) : 6057 - 6066
  • [10] Tolerance and Toxicity of the PARP Inhibitor Olaparib in Older Women with Ovarian Cancer
    Dockery, L.
    Tew, W.
    Moore, K.
    Ding, K.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 197 - 198
12345